Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2023-11-04
DOI
10.1200/jco.23.00573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer
- (2023) Martin K. Bakht et al. Nature Cancer
- Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer
- (2021) Panagiotis J. Vlachostergios et al. PROSTATE
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- 177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial
- (2021) Sarennya Pathmanandavel et al. JOURNAL OF NUCLEAR MEDICINE
- Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312
- (2021) Jeremie Calais et al. JOURNAL OF NUCLEAR MEDICINE
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
- (2019) Edoardo Francini et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Radionuclide Therapy of Metastatic Prostate Cancer
- (2019) Clemens Kratochwil et al. SEMINARS IN NUCLEAR MEDICINE
- Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2019) Scott T. Tagawa et al. CANCER
- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
- (2018) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
- (2015) N. Pandit-Taskar et al. CLINICAL CANCER RESEARCH
- 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
- (2014) Neeta Pandit-Taskar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of -Particle Emitters for Targeted Radionuclide Therapy
- (2010) G. Sgouros et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search